1. Home
  2. GTLB vs XOMAP Comparison

GTLB vs XOMAP Comparison

Compare GTLB & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GTLB
  • XOMAP
  • Stock Information
  • Founded
  • GTLB 2011
  • XOMAP N/A
  • Country
  • GTLB United States
  • XOMAP United States
  • Employees
  • GTLB N/A
  • XOMAP 13
  • Industry
  • GTLB EDP Services
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • Sector
  • GTLB Technology
  • XOMAP Health Care
  • Exchange
  • GTLB Nasdaq
  • XOMAP Nasdaq
  • Market Cap
  • GTLB N/A
  • XOMAP N/A
  • IPO Year
  • GTLB 2021
  • XOMAP N/A
  • Fundamental
  • Price
  • GTLB $55.05
  • XOMAP $25.80
  • Analyst Decision
  • GTLB Buy
  • XOMAP
  • Analyst Count
  • GTLB 26
  • XOMAP 0
  • Target Price
  • GTLB $66.56
  • XOMAP N/A
  • AVG Volume (30 Days)
  • GTLB 3.0M
  • XOMAP N/A
  • Earning Date
  • GTLB 09-03-2024
  • XOMAP N/A
  • Dividend Yield
  • GTLB N/A
  • XOMAP N/A
  • EPS Growth
  • GTLB N/A
  • XOMAP N/A
  • EPS
  • GTLB N/A
  • XOMAP N/A
  • Revenue
  • GTLB $622,215,000.00
  • XOMAP N/A
  • Revenue This Year
  • GTLB $29.56
  • XOMAP N/A
  • Revenue Next Year
  • GTLB $24.52
  • XOMAP N/A
  • P/E Ratio
  • GTLB N/A
  • XOMAP N/A
  • Revenue Growth
  • GTLB 34.15
  • XOMAP N/A
  • 52 Week Low
  • GTLB $40.19
  • XOMAP N/A
  • 52 Week High
  • GTLB $78.53
  • XOMAP N/A
  • Technical
  • Relative Strength Index (RSI)
  • GTLB 60.85
  • XOMAP 55.73
  • Support Level
  • GTLB $52.30
  • XOMAP $25.32
  • Resistance Level
  • GTLB $56.50
  • XOMAP $26.00
  • Average True Range (ATR)
  • GTLB 2.10
  • XOMAP 0.36
  • MACD
  • GTLB 0.45
  • XOMAP -0.02
  • Stochastic Oscillator
  • GTLB 83.60
  • XOMAP 55.37

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: